Financial Comparison: Revance Therapeutics (NASDAQ:RVNC) vs. PureTech Health (NASDAQ:PRTC)

Revance Therapeutics (NASDAQ:RVNC) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Insider and Institutional Ownership

97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Revance Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Revance Therapeutics and PureTech Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revance Therapeutics	0	8	1	0	2.11
PureTech Health	0	0	1	1	3.50

Revance Therapeutics presently has a consensus target price of $10.29, suggesting a potential upside of 94.81%. PureTech Health has a consensus target price of $45.00, suggesting a potential upside of 119.51%. Given PureTech Health’s stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Revance Therapeutics.

Profitability

This table compares Revance Therapeutics and PureTech Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revance Therapeutics	-117.88%	N/A	-41.05%
PureTech Health	N/A	N/A	N/A

Valuation & Earnings

This table compares Revance Therapeutics and PureTech Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revance Therapeutics	$234.04 million	2.36	-$323.99 million	($3.19)	-1.66
PureTech Health	$3.33 million	147.33	-$65.70 million	N/A	N/A

PureTech Health has lower revenue, but higher earnings than Revance Therapeutics.

Summary

PureTech Health beats Revance Therapeutics on 9 of the 11 factors compared between the two stocks.

About Revance Therapeutics

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.